Last reviewed · How we verify

Standard TB treatment — Competitive Intelligence Brief

Standard TB treatment (Standard TB treatment) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimycobacterial combination therapy. Area: Infectious Disease.

phase 3 Antimycobacterial combination therapy Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Standard TB treatment (Standard TB treatment) — The Aurum Institute NPC. Standard TB treatment uses a combination of antimicrobial agents that inhibit bacterial cell wall synthesis and protein synthesis to kill or suppress Mycobacterium tuberculosis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Standard TB treatment TARGET Standard TB treatment The Aurum Institute NPC phase 3 Antimycobacterial combination therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimycobacterial combination therapy class)

  1. The Aurum Institute NPC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Standard TB treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-tb-treatment. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: